On Monday, September 21, two University of Mississippi students were found dead in separate residences in Oxford. Investigators reportedly recovered packaged kratom, said to have been purchased from a retail store, at both scenes. To date, no official cause of death has been established. Those details should remain attributed to investigators or local reporting unless supported by official records. More recent reporting has linked the two deaths of the college students to a nearby drug bust.

Even so, the cases raise a question that deserves more attention: How can a product sold in gas stations, bodegas and other retail settings become part of a death investigation?

For more than a decade, kratom has been marketed as a “natural” wellness product. But “natural” tells us almost nothing about safety. Kratom’s pharmacology is more complicated, and the risks may vary considerably depending on the product, dose, formulation and other substances involved.

An Opioid In A Supplement’s Clothing

Kratom comes from the leaves of Mitragyna speciosa , a tree native to Southeast Asia. Its principal alkaloid, mitragynine, interacts with opioid receptors. Its derivative 7-hydroxymitragynine, or 7-OH, has more potent opioid-receptor activity.

Lewis S. Nelson, MD, MBA , Dean and Professor of Emergency Medicine and Medical Toxicology at Florida Atlantic University’s Schmidt College of Medicine, describes kratom as “an opioid-like botanical product marketed as a dietary supplement for its psychoactive effects and for self-management of opioid withdrawal.”

That distinction matters because kratom products are not all the same. Traditional kratom leaf may contain relatively small amounts of 7-OH , while some concentrated tablets, gummies and shots are marketed with higher or added 7-OH content.

Nelson says that difference may be clinically important. “More recently, 7-hydroxymitragynine (7-OH), a mitragynine derivative with substantially more potent opioid-like activity, has emerged in concentrated commercial products and appears to carry a greater risk of respiratory depression and poor outcomes.”

Traditional plant-based kratom and concentrated 7-OH products should not be treated as interchangeable. That does not mean every traditional product is safe. Product composition, dose, co-exposures and a person’s underlying health can all change the risk.

“Traditional plant-based kratom products are unlikely to produce fatal respiratory depression when taken alone, even in substantial overdose,” Nelson said. “In contrast, concentrated 7-OH products have substantially greater opioid activity and therefore pose a greater risk of clinically significant respiratory depression and poor outcomes.”

When respiratory depression has occurred in reported cases, it has generally responded to naloxone, according to Nelson. That observation should not be treated as a guarantee, but it reinforces the importance of recognizing opioid-like toxicity quickly.

What Clinicians Are Seeing

Reported neurologic complications after kratom exposure include agitation, confusion, seizures, syncope, hallucinations, ataxia and coma. These conditions are not necessarily common, and many reports involve other substances. Still, they are important enough that emergency physicians should inquire about kratom when a patient presents with an unexplained neurologic emergency.

Seizures have been reported in poison-center data and case reports, including in some patients without a known seizure disorder. Reports of intracranial hemorrhage and other severe neurologic events have also appeared in the medical literature. Those reports document temporal associations; they do not prove that kratom caused the events. But they do justify clinical awareness.

Diagnosis can be difficult. Kratom and 7-OH are not routinely identified by many standard hospital toxicology screens , although testing capabilities vary by institution. Specialized confirmatory testing may require a send-out assay and may not return for days.

That means a patient with an unexplained seizure, altered mental status or respiratory depression can have a negative routine drug screen while kratom, 7-OH or another untested substance remains relevant.

There is another important issue: clinicians and consumers may not know what is actually contained in the product.

“Because these products are poorly regulated, there is considerable variability in their concentration, purity, and labeling,” explained Nelson.

The overriding concern is that kratom products are not uniformly standardized or subject to one comprehensive national testing system. Commercial products may vary in alkaloid concentration and labeling accuracy. Products obtained from informal or illicit sources may also contain adulterants or contaminants, although claims that they routinely contain ultra-potent opioids require specific testing data.

The practical issue is uncertainty. Consumers may not know the dose, concentration, purity or complete composition of what they are taking.

Lack Of Clarity About The Deaths In Mississippi

The University of Mississippi cases intensified concern, but they also show why careful language matters.

The date, locations, recovered products and source of those details should remain attributed to law enforcement, the university, the medical examiner or named news reports. Official toxicology results are generally released in a matter of weeks.

Nelson said that “the occurrence of two deaths in young people in close temporal and geographic proximity raises concern for exposure to a common product or adulterant.” That is a clinical hypothesis, not evidence that a common product was involved.

One possibility, he noted, would be exposure to a concentrated 7-OH product or adulteration with a highly potent synthetic opioid. But without toxicology or product testing, that possibility should not be presented as the leading explanation.

“Definitive conclusions,” Nelson emphasized, “would require comprehensive toxicologic testing of both the decedents and any implicated products.”

Finding kratom packaging at a death scene does not establish that kratom caused the death. Polysubstance exposure is another possible explanation, but it is only one hypothesis among several unless investigators release supporting evidence.

The public conversation should avoid both extremes: dismissing kratom because it is legally sold and declaring it responsible for deaths before toxicology results establish what what actually occurred.

Dependence May Be The More Immediate Threat

For some users, the more immediate harm may be dependence rather than fatal overdose.

Regular kratom use has been associated with tolerance and an opioid-like withdrawal syndrome. Clinicians have described severe withdrawal and rapid dependence after the use of concentrated 7-OH products . Some reported patients had no prior heroin, fentanyl or prescription-opioid use. Others said they had turned to kratom in an effort to stop using opioids.

Those reports should not be generalized to every user, but they challenge the idea that kratom is simply a harmless substitute for conventional opioids.

Kratom-related deaths reported in mortality and poison-center studies often involve other substances (coingestants), although the frequency depends on the dataset and how cases are defined. Alcohol, benzodiazepines, prescription opioids, fentanyl and other sedating drugs can increase the risk of respiratory depression when combined with opioid-like substances.

College populations may warrant particular attention. In a Healthy Minds Study analysis involving more than 81,000 students, kratom use was associated with depressive symptoms and alcohol and cannabis use. Because the analysis was observational, it cannot show that kratom caused those conditions.

Some students may also use kratom to self-treat anxiety, depression, pain, insomnia or withdrawal. That possibility should be understood as a reported motivation, not an assumption about all users.

Fixing The Public Health Messaging

The first change should be semantic: “natural” should not be treated as synonymous with safe.

Consumers should understand that kratom contains compounds with opioid-receptor activity and that concentrated 7-OH products may have greater opioid activity than many traditional leaf preparations.

Michigan’s health department offers one possible model in its campus materials . Public-health messaging should explain what 7-OH is, show students what products may look like, warn about combining kratom or 7-OH with alcohol, benzodiazepines or other opioids, and identify the signs of an emergency. Someone who is difficult to awaken or breathing inadequately needs immediate medical help.

Naloxone should also be considered part of a broader harm-reduction strategy wherever opioid-like products are being used. That is a policy recommendation, but it is a practical one given the potential for opioid-like respiratory depression.

Campus naloxone programs, orientation sessions, residence-hall education and student-health screening could include information about kratom and 7-OH. These interventions should be evaluated rather than assumed to work simply because they sound sensible.

Accurate labeling of alkaloid content, age restrictions, product testing and interaction warnings are also reasonable regulatory goals. The marketplace may not consistently provide consumers with that information.

Clinicians should ask about kratom by name. Patients may not consider a powder, gummy or brightly colored shot to be a drug, and a general question about “supplements” may not be enough.

Regulation Must Keep Pace

Kratom imported into the United States is associated with Southeast Asia, and Indonesia is widely identified as a major source. Bulk leaf material may then be packaged or processed domestically.

Some products may also be processed or manufactured domestically from imported botanical material. The supply chain is important because border enforcement alone cannot address every product sold in the United States.

FDA and Customs enforcement are only part of the regulatory picture. Stronger oversight could include clearer composition standards, laboratory verification of alkaloid content, more accurate labeling, and action against adulterated or deceptively marketed products.

Regulators should also consider whether traditional kratom leaf and concentrated or chemically altered derivatives should be treated as separate categories. That is a policy position, not an established consensus, but the pharmacologic differences make the question difficult to ignore.

Relief for People Who Are Struggling

People who develop kratom or 7-OH dependence deserve treatment rather than blame.

“Treatment of kratom use generally follows that of opioid use disorder,” Nelson emphasized, including tapering, use of an opioid agonist such as buprenorphine , and psychosocial therapy and support.

Treatment decisions require individualized medical assessment. The published evidence for buprenorphine in kratom dependence remains limited, consisting largely of case reports, case series and observational reports rather than randomized trials. Evidence involving traditional kratom should not automatically be generalized to concentrated 7-OH products , for which the clinical literature may be even more limited.

Still, the basic principle is clear: dependence should not go untreated simply because the substance came from a supplement aisle rather than a pharmacy.

Campus health centers, emergency departments, primary-care practices and addiction programs should be prepared to identify possible kratom-related dependence and connect patients with addiction and mental-health care.

Kratom’s greatest danger may ultimately be its disguise. A plant-derived powder, gummy or shot may not resemble a conventional opioid. But concentrated 7-OH products can have opioid-like effects, and consumers may have limited information about potency, purity or contamination.

The evidence does not show that every kratom exposure is lethal. Packaging found at a death scene does not prove causation. It does show that consumers may face uncertainty about product composition and that concentrated products warrant separate attention.

Students, parents and clinicians deserve accurate information. People who develop dependence deserve access to evidence-informed treatment rather than judgment.

Dr. Peter Papadakos , Professor of Anesthesiology and Critical Care at University of Rochester Medical Center is a contributor to this article.